SummaryRMgm-4688
|
Successful modification | The parasite was generated by the genetic modification |
The mutant contains the following genetic modification(s) | Gene disruption |
Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 31553751 |
MR4 number | |
top of page | |
Parent parasite used to introduce the genetic modification | |
Rodent Malaria Parasite | P. berghei |
Parent strain/line | P. berghei ANKA |
Name parent line/clone | Not applicable |
Other information parent line | |
top of page | |
The mutant parasite was generated by | |
Name PI/Researcher | CurrĂ C, Mair GR |
Name Group/Department | Institute of Molecular Biology and Biotechnology |
Name Institute | FORTH |
City | Heraklion |
Country | Greece |
top of page | |
Name of the mutant parasite | |
RMgm number | RMgm-4688 |
Principal name | omd(-)cl1 and omd(-)cl2 |
Alternative name | |
Standardized name | |
Is the mutant parasite cloned after genetic modification | Yes |
top of page | |
Phenotype | |
Asexual blood stage | Not different from wild type |
Gametocyte/Gamete | Not different from wild type |
Fertilization and ookinete | Ookinete formation did not reveal a significant difference between mutant and WT parasite development with ookinete morphologies similar as revealed by Giemsa-stained smears and scanning electron microscopy analysis. Ookinetes were also formed in vivo as revealed by Giemsa stained smears of mosquito midguts formed 24 h after feeding on an infected mouse. Mature omd(-) ookinetes were completely devoid of productive motility; at most they displayed stretching of the ookinete. In vivo transmission experiments, where mosquitoes are allowed to blood feed on mice infected with the omd(-)cl1 mutant, did not result in the establishment of oocysts in three independent feedings; WT parasites on the other hand transmitted normally. |
Oocyst | In vivo transmission experiments, where mosquitoes are allowed to blood feed on mice infected with the omd(-)cl1 mutant, did not result in the establishment of oocysts in three independent feedings; WT parasites on the other hand transmitted normally. |
Sporozoite | No oocyst and sporozoite formation |
Liver stage | No oocyst and sporozoite formation. No transmission to mice by bite of infected mosquitoes. |
Additional remarks phenotype | Mutant/mutation Phenotype Evidence is presented for absence of expression of OMD in asexual blood stages and in liver stages. Evidence is presented that the failure of ookinete motility in the omd(-) mutant is not due to gross mis-localization of either micronemal proteins or components of the motility machinery. |
top of page | |||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||
Gene Model of Rodent Parasite | PBANKA_0407300 | ||||||||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_0309100 | ||||||||||||||||||||||||
Gene product | OMD protein, putative | ||||||||||||||||||||||||
Gene product: Alternative name | ookinete motility deficient, OMD | ||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||
Inducable system used | No | ||||||||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||||||||
Type of plasmid/construct used | (Linear) plasmid double cross-over | ||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||
Restriction sites to linearize plasmid | |||||||||||||||||||||||||
Partial or complete disruption of the gene | Complete | ||||||||||||||||||||||||
Additional remarks partial/complete disruption | |||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | hdhfr/yfcu | ||||||||||||||||||||||||
Promoter of the selectable marker | eef1a | ||||||||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||||||||
Additional remarks genetic modification | |||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||
Primer information: Primers used for amplification of the target sequences
![]() Primer information: Primers used for amplification of the target sequences
![]()
| |||||||||||||||||||||||||
top of page |